The recent advancements in atherosclerosis pathophysiology indicate that inflammation plays a significant role. With trials such as COLCOT and LoDoCo showing benefit of colchicine in CAD, there is a possibility of expansion of our current armamentarium in secondary prevention of CAD. However, further study is needed to change practice and to evaluate the utility of colchicine in ACS. Early data have shown CV benefits of certain other gout medications, but there are no current FDA-approved indications in cardiology. Febuxostat, earlier thought to have a poor cardiovascular outcome compared with allopurinol, was found to be non-inferior to allopurinol and with no increase in mortality in the recent FAST trial. Overall, more evidence is required to definitively endorse clinical use of these drug classes in CAD.
No sources of funding were used to assist in the preparation of this article.
Consent to participate
Consent for publication
Availability of data and material
Am J Cardiovasc Drugs. 2021;21(5):499-512. © 2021 Adis Springer International Publishing AG